Iplex Market Report 2026

Iplex Market Overview

• The Iplex market growth in the historic period has been driven by recognition of severe igf 1 deficiency, limitations of growth hormone therapy • Market expansion is supported by improved diagnosis of growth disorders, expansion of pediatric endocrinology services • Growth Driver: Rising Growth Hormone Deficiencies Drive Expansion Of The Iplex Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Iplex Market?

Iplex (mecasermin rinfabate) is a recombinant human insulin-like growth factor-1 (IGF-1) complexed with IGF binding protein-3 (IGFBP-3). It is used to treat severe primary IGF-1 deficiency, promoting growth in children. By stabilizing IGF-1, it enhances cellular growth, metabolism, and development while minimizing hypoglycemia risks associated with free IGF-1. The main patient demographics for iplex are pediatric and age groups. Pediatric patients refer to individuals aged 0 to 18 years who require specialized medical care for growth and development. Iplex is used in these patients to treat growth hormone deficiencies by providing targeted IGF-1 therapy, promoting proper growth and development when traditional treatments are ineffective. It is distributed through channels such as hospitals, retail pharmacies, specialty pharmacies, and online pharmacies, and is utilized for various applications, including growth hormone deficiency and others.

What Is The Iplex Market Growth Forecast?

The growth in the forecast period can be attributed to improved diagnosis of growth disorders, expansion of pediatric endocrinology services, rising awareness among caregivers, continued orphan drug support, advancements in recombinant protein production. Major trends in the forecast period include treatment of rare pediatric growth disorders, use of recombinant growth factor therapies, focus on reducing hypoglycemia risk, specialized endocrinology care expansion, long term pediatric hormonal management.

Global Iplex Market Segmentation

1) By Patient Demographics: Pediatric Patients, Age Groups 2) By Distribution Channel: Hospitals, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies 3) By Application: Growth Hormone Deficiency, Other Applications

What Are The Drivers Of The Iplex Market?

The increasing prevalence of growth hormone deficiencies (GHD) is anticipated to drive the expansion of the iplex (mecasermin rinfabate) market. Growth hormone deficiencies (GHD) refer to a condition where the pituitary gland produces insufficient growth hormone, leading to impaired physical growth and developmental issues in children and adults. The rise in the incidence of growth hormone deficiencies is attributed to improved diagnostic techniques, better awareness of endocrine disorders, and increased prevalence of conditions such as genetic mutations, tumors, or traumatic brain injuries that can impair growth hormone production. Iplex (mecasermin rinfabate) is used to treat growth hormone deficiencies by providing insulin-like growth factor-1 (IGF-1) combined with IGF-binding protein-3 to promote growth and metabolic activity. For instance, in October 2024, according to a report published by the Cystic Fibrosis Trust, a UK-based non-professional organization, the UK cystic fibrosis registry exceeded 11,318 individuals in 2023, with adults representing a substantial share of the patient base, as 63.7% were aged over 16 and 16.7% were over 40, underscoring a growing and ageing CF population. Therefore, the rising incidence of growth hormone deficiencies (GHD) is expected to fuel the growth of the iplex industry. The increasing pediatric population is expected to propel the growth of the iplex market. The pediatric population includes individuals from birth to 18 years, requiring specialized care for growth, development, and age-specific medical needs. The expanding pediatric population is driven by higher birth rates, improved healthcare reducing child mortality, and increasing awareness of childhood health needs, resulting in growing demand for pediatric services and treatments. Iplex is useful in the expanding pediatric population by providing targeted IGF-1 therapy for children with growth hormone deficiencies, helping promote proper growth and development in cases where traditional treatments are ineffective. For instance, in July 2025, according to the Centers for Disease Control and Prevention an US-based government agency reported that the number of births in the United States increased 1% from 2023 to 2024, to 3,628,934 births. Therefore, this expanding pediatric population is a key driver of growth in the iplex industry. The increasing investment in healthcare research and development is expected to propel the growth of the iplex market going forward. Healthcare research and development involves scientific studies to discover new treatments, enhance therapies, and innovate technologies for better patient care and public health. Increasing investment in healthcare research and investment is driven by the need for innovative treatments, advancements in technology, and the growing burden of chronic and rare diseases, ensuring improved healthcare outcomes and addressing unmet medical needs. Increasing investment in healthcare research and development supports iplex manufacturing and development by funding innovation, improving treatment efficacy, and enhancing production capabilities. For instance, in January 2025, according to the National Institutes of Health a US-based government agency reported that the NIH invests most of its nearly $48 billion budget in medical research seeking to enhance life and to reduce illness and disability. Therefore, increasing investment in healthcare research and development is driving the growth of the iplex industry.

Key Players In The Global Iplex Market

Major companies operating in the iplex market are Insmed Incorporated

Regional Insights

North America was the largest region in the Iplex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Iplex Market?

The iplex market consists of sales of mecasermin rinfabate (rDNA origin) injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Iplex Market Report 2026?

The iplex market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the iplex industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.